AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04884815 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: UX701
Description: Nonreplicating, recombinant gene transfer vector
Study NCT04884815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline
Study NCT06242470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose Escalation
Description: Escalating doses of MGC026
Study NCT06242470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGC026 Dose for Expansion
Description: MGC026 recommended dose for expansion
Study NCT05266027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Sebacate (Naldebain)
Description: Nalbuphine Sebacate (Naldebain) 2mL/150mg would be intramuscularly injected during knee arthroplasty surgery.
Study NCT05266027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medication
Description: Placebo medication, Nalbuphine Sebacate not contained
Study NCT04900623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NavDx HPV ctDNA Testing
Description: Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.
Study NCT04900623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.
Study NCT05062200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered as an oral tablet.
Study NCT05346393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
Study NCT05346393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
Study NCT05314504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Cross-linked sodium hyaluronate gel for injection with lidocaine
Study NCT05621915 — intervention group
Intervention type: DRUG
Intervention: Nadroparin
Description: Subcutaneous injection of nadroparin according to the ICU guidelines for thromboprophylaxis in ICU patients.
Study NCT05070728 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injector
Description: Intravitreal sham injection
Study NCT05070728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FAI Insert
Description: Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle.
Study NCT05183893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 5 g of L-citruline + 5 g of additives
Study NCT05183893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citrulline-malate
Description: 8g of citrulline-malate + 2 g of additives
Study NCT05183893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10g of maltodextrine
Study NCT05428098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Oral and written education according to the life model
Study NCT04900623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.
Study NCT06236880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-2505
Description: IV
Study NCT05689697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PanTrek
Description: administration of exogenouse keton body
Study NCT05689697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PanTrek
Description: administration of exogenouse keton body
Study NCT04769310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac and Brain MRI
Description: A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI
Study NCT06310044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal irrigant Commiphora Myrrh 50%
Description: Root canal irrigant
Study NCT06310044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root canal irrigant Commiphora Myrrh 50%
Description: Root canal irrigant
Study NCT05969431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of cortisol level
Description: We will measure the cortisol level from the hair sample of the father at three time points. Furthermore the father will answer questionnaires at three time points and the paternal sensitivity is measured once.
Study NCT06557174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-002
Description: intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Study NCT06557174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil， MMF
Description: daily oral 0.2g
Study NCT04728451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle wear support
Description: Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
Study NCT04728451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
Study NCT05873439 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Genomically Guided Radiation Therapy (RT)
Description: Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
Study NCT05135663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
Study NCT05135663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-089/NCNP-02
Description: The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 216 weeks (The total treatment period is 240 weeks including Part2 of Study NCNP/DMT02).
Study NCT05201924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedtime routine
Description: a regular routine conducted around bedtime includes brush, book reading and regular bedtime
Study NCT05201924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: a healthy control checklist
Study NCT06369467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linvoseltamab
Description: Administered by intravenous (IV) infusion
Study NCT06369467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection
Study NCT03690011 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD7.CAR/28zeta CAR T cells
Description: Three dose levels will be evaluated:~* Dose level one: 1×10\^7 cells/m\^2~* Dose level two: 3×10\^7 cells/m\^2~* Dose level three: 5x10\^7 cells/m\^2~* Dose level four: 1×10\^8 cells/m\^2
Study NCT06388434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Arm Balance Response Training
Description: Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
Study NCT06419179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg i.v. Q4W
Study NCT06419179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID orally
Study NCT06248411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK2260
Description: KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
Study NCT05350501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EO2040
Description: EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by three human doctors
Description: This intervention involves answering patient inquiries by different human doctors. Each patient is randomly assigned by the system to three doctors from different provinces in China selected from the database of doctors. The doctors all come from multiple online consultation platforms in China, and their diagnostic qualifications and medical licenses have undergone strict verification.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-3.5 (without search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-3.5 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-4.0 (with search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-4.0 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06011967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intubation using C-MAC D blade videolariyngoscope
Description: all patients were intubated using the C-MAC D-Blade videolaryngoscope but for each group the intubation tubes were angled in different degrees. First group was intubated using the stylet of 60 degrees, second group was intubated using the stylet of 80 degrees and the third group was intubated using the stylet of 90 degrees.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by ChatGPT-4.0 (without search capabilities)
Description: This intervention involves answering patient inquiries by ChatGPT-4.0 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Claude instant (with search capabilities)
Description: This intervention involves answering patient inquiries by Claude instant with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Claude instant (without search capabilities)
Description: This intervention involves answering patient inquiries by Claude instant without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Claude 2 (with search capabilities)
Description: This intervention involves answering patient inquiries by Claude 2 with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Claude 2 (without search capabilities)
Description: This intervention involves answering patient inquiries by Claude 2 without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Gemini Pro (with search capabilities)
Description: This intervention involves answering patient inquiries by Gemini Pro with search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT06457269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnosis by Gemini Pro (without search capabilities)
Description: This intervention involves answering patient inquiries by Gemini Pro without search capabilities, before answering any questions, clear the chat history from the previous patient and input the predetermined initialization statement.
Study NCT05672108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05672108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethiodized Oil
Description: Given IA
Study NCT05672108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IA
Study NCT05672108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE
Study NCT05672108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tris-acryl Gelatin Microspheres
Description: Given IA
Study NCT05646277 — intervention group
Intervention type: OTHER
Intervention: e-Consultation
Description: first orthodontic consultation in remote
Study NCT05646277 — intervention group
Intervention type: OTHER
Intervention: Consultation
Description: first orthodontic consultation in face-to-face
Study NCT06236243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Extract Powder 120 mg/tablet
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
Study NCT06236243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Korean Red Ginseng Extract Powder 500 mg/tablet
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
Study NCT06236243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 2 tablets 2 times daily (preferably after breakfast and after dinner) for 12 weeks.
Study NCT06533423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention (NISMA)
Description: The NISMA intervention is a flexible intervention and comprises three mandatory individual sessions with a nurse, supplemented by two optional group sessions over a period of 12 months, to provide comprehensive support tailored to each participant's needs. The intervention is grounded in the theoretical framework Social Cognitive Theory and inspired by the questioning techniques in Acceptance and Commitment Therapy (ACT). These methods play a crucial role in helping participants enhance their self-efficacy. The key components of our approach include: a person-centered approach by addressing challenges identified by each participant to foster self-efficacy through targeted problem-solving and goal-setting. This is utilized by interviewing techniques derived from ACT to assist participants in accepting and committing to self-management. The program is designed to last between 6-12 months, allowing for gradual skill development and adaptation.
Study NCT06340178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid application during ct-guided lung biopsy
Description: Injection of a small amount of fluid (max. 20 ml sodium chlorid) in the pleural cavity at the biopsy site
Study NCT06551142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK5764227
Description: GSK5764227 will be administered
Study NCT06551142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan will be administered
Study NCT05240534 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ET-Text (Laptop)
Description: ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop.
Study NCT05240534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ET-Voice (Smart System)
Description: ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience.
Study NCT05765812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123
Description: Administered as capsules.
Study NCT05765812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered as capsules.
Study NCT05765812 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered in accordance with the local clinical practice and applicable Radiation Therapy Oncology Group (RTOG) or the European Organization for Research and Treatment of Cancer (EORTC) guidelines.
Study NCT05062200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral tablet.
Study NCT06552364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA+LAMA
Description: 1 dose per day (AM)
Study NCT06552364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LABA+LAMA
Description: 1 dose per day (AM)
Study NCT06552364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA+LAMA+ICS
Description: 1 dose per day (AM)
Study NCT06552364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA+LAMA+ICS
Description: 1 dose per day (AM)
Study NCT06552364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control
Study NCT06552364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air
Description: Exposure to HEPA filtered air, as a control
Study NCT06552364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
Study NCT06552364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel Exhaust
Description: Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).